The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

Description

This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.

Conditions

Neonatal Thrombocytopenia, Bleeding

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a prospective observational study designed to evaluate Immature Platelet Fraction or Immature Platelet Count and Platelet Function Analyzer-100/200 Closure Time-ADP (in vitro bleeding time) as markers of bleeding risk in thrombocytopenic preterm neonates admitted to the Neonatal Intensive Care Unit.

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study-2

The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

Condition
Neonatal Thrombocytopenia
Intervention / Treatment

-

Contacts and Locations

Boston

Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Boston

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02215

Murray

Intermountain Medical Center, Murray, Utah, United States, 84107

Provo

Utah Valley Hospital, Provo, Utah, United States, 84604

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have a gestational age \<32 weeks and a birth weight ≥500 grams;
  • * Have a platelet count \<100 x 109/L; and
  • * Have a parent/guardian willing to provide written informed consent.
  • * Are not expected to survive for \>24 hours by the Attending Neonatologist;
  • * Are thought to have a familial thrombocytopenia or platelet dysfunction, based on family history or clinical presentation (associated congenital malformations, platelet morphology).

Ages Eligible for Study

1 Day to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Karolinska Institutet,

Emöke Deschmann, MD, PhD, PRINCIPAL_INVESTIGATOR, Karolinska Institutet

Robert Christensen, MD, STUDY_CHAIR, University of Utah Medical Center

Study Record Dates

2025-12-31